奥希替尼用于 EGFR+晚期非小细胞肺癌患者一线治疗的药物经济学评价
刘心怡,陈文
奥希替尼用于 EGFR+晚期非小细胞肺癌患者一线治疗的药物经济学评价
Pharmacoeconomic evaluation of osimertinib in the first-line treatment of locally advanced or metastatic NSCLC with an EGFR mutation
{{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
〈 | 〉 |